NCT02926586View on ClinicalTrials.gov

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

August 16, 2020

Study Completion Date

July 31, 2024

Conditions
Acute Myeloid LeukemiaCore-Binding Factor
Interventions
DRUG

Fludarabine

Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4

DRUG

Cytarabine

2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4

Trial Locations (1)

200080

Xianmin Song, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT02926586 - Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | Biotech Hunter | Biotech Hunter